

--- QUAD STATS ---

FILE: #12:123/CD2019 SAMPLE: 059

DATE: 9/24/92 GATE G1-R1


PARAMETER: FL1-H\LOG FL2-H\LOG QUAD LOCATION: 17.15 9

TOTAL = 5000 GATED = 1290


QUAD EVENTS % GATED % TOTAL X MEAN Y MEAN

| QUAD | EVENTS | % GATED | % TOTAL | X MEAN | Y MEAN |
|------|--------|---------|---------|--------|--------|
| IUL | 299 | 23.18 | 3.98 | 11.41 | 284.69 |
| 2UR | 831 | 65.97 | 17.02 | 32.70 | 630.65 |
| 3LL | 135 | 10.47 | 2.70 | 4.08 | 3.31 |
| 4LR | 5 | 0.39 | 0.10 | 25.11 | 6.34 |

■ ACO CMB INSTR-CTRL GATES FORMAT PROTO SAVE



■ ACO CMD INSTR-CTRL GATES FORMAT PROTO SAVE



Leu5-b

ELAPSED TIME

[00:00:33]

09056022 - 040298

FIG. 3A'
PBMC WITHOUT LO-CD2- α






FIG. 3B
PBMC WITH LO-CD2- α



3620400 22095060

FIG. 4



Effects of LO-CD2a on resting
Cells during MLC




FIG. 8A

00000000000000000000000000000000

7/41

FIG. 5B





FIG. 5A



3620400-22095060







FIG. 6D



9/41

MLC: LEU-5b+ (CD2+) CELLS






FIG. 8B

2020-09-24 09:00:00

26.2.1980 - 2205060


FIG. 7



Number of cells/25,000 survivors and analyzed per 1000 survivors

Figure 9


Effects of LO-CD2-a on mitogen-stimulated PBMC




09056072 040798

0000500000000000

12 / 41





86520410" 22095060

14/41





FIG. 10


OKT3 PHA CON-A MITOGENS ADDED AT DAY 0.

LYMPHOCYTE COUNTS




LOC D2 20mg/DAY
D0-D9

CELL POPULATIONS FIG. 13
 LOC D2: 20 mg/DAY
 DO - D9



86-20400-22095060

FIG. 14



862040 " 22095060

18/41

LOCD2- α SERUM CONCENTRATION
CYNOMOLGUS MONKEY 1992






FIG. 15

Digitized by srujanika@gmail.com

FIG. 16

IgG ANTI-LOC2a
CYNOMOLGUS MONKEY





36400400 " 2200950600

21620410-22025060

FIG. 18A




FIG. 18B






FIG. 19



23 / 41

CREATININE 3 g/dl OF BLOOD



26/10/00 22095060

24/41

FIG. 21

LO-CD2- α IN KIDNEY ALLOGRAFT REJECTION




FIG. 22





FIG. 23



27/4/1980

LO-CD2- α IN KIDNEY ALLOGRAFT REJECTION
PATIENT 2 (A.A.)

FIG. 24











FIG. 25



262040" 2409150610

29 / 41



SINGLE STAINED CONTROLS

262040-2206500

30/41

SINGLE STAINED CONTROLS

#12:15/L0-30001
50%LOG




FIG. 26J
#12:13/L0-30013
50%LOG




FIG. 26G
#12:15/L0-30016
50%LOG




FIG. 26H
#12:15/L0-30017
50%LOG





FIG. 26I
#12:15/L0-30014
50%LOG



0620400 " 22095060

31/141
FIG. 27A




FIG. 27B




FIG. 27C




FIG. 27D




FIG. 27E





FIG. 27F



0062040056000000









FIG. 28A

12/13/TRANS 2001
FLI-H\FLI-HEIGHT




FIG. 28B

12/13/TRANS 2013
FLI-H\FLI-HEIGHT




FIG. 28C

12/13/TRANS 2001
FLI-H\FLI-HEIGHT




FIG. 28D

12/13/TRANS 2013
FLI-H\FLI-HEIGHT




FIG. 28E

12/13/TRANS 2005
FLI-H\FLI-HEIGHT

RAT IgG2b

LO-CD2a




FIG. 28F

12/13/TRANS 2017
FLI-H\FLI-HEIGHT

RAT IgG2b (7%)

LO-CD2a (52%)



09056072-040296

Lo-CD2a VI. + Native Leader Sequence

Sequence Range: 1 to 761

| 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90 | 100 |
|---|----|----|----|----|----|----|----|----|-----|
| * | * | * | * | * | * | * | * | * | * |
| ATGATGAGTCCTGCCAGTCCCTGTTCTGTTATGCTTGGATTCTGGTAAGTAGAGAATGAGTTACAGGACAAGAATGGGGATGGAGGATGAGTCT | | | | | | | | | |
| M M S P V Q S L F L L L W I L G> | | | | | | | | | |
| -20 | | | | | | | | | |
| * | * | * | * | * | * | * | * | * | * |
| GACTGCCCATGTTGGCTGTCATGTGTGGTAAGGCAGGTCTATTCTAAGATGGACACTTGAGATTCCATTACTTGATAATGAGAATTACAGATGAG | | | | | | | | | |
| * | * | * | * | * | * | * | * | * | * |
| ATAGGAAFTGCTAAGAGGATCTAATGTTAGATGAGATGAGAAAGCTGTATGCCATTAGGATCTGCCAACCGAATGTTGTGAAAGCATTGGTATATT | | | | | | | | | |
| * | * | * | * | * | * | * | * | * | * |
| TTAAAATCACAAACACCGGGATCTCACAGGAATGAGTAACAAAAGTAATTCACAAAGATTTGGTGCACAAATTGGCATAACTTGTCTGATC | | | | | | | | | |
| * | * | * | * | * | * | * | * | * | * |
| 410 420 430 440 450 460 470 480 490 500 | | | | | | | | | |
| TATTATAATTTCAGGAACCAATGGTATGTTGCTGACCCAGACTCCACCTACTTTATTGGCTACCCATTGGACANTCAGTCTCCATCTCTTGCAAGGTCA | | | | | | | | | |
| T N G D V V L T Q T P P T L L A T I G Q S V S I S C R S > | | | | | | | | | |
| 510 | | | | | | | | | |
| * | * | * | * | * | * | * | * | * | * |
| AGTCAGAGTCTTACATAGTAGTGGAACACACTATTAAATTGTTGCTACAGAGGACAGGCCAATCTCCACAGCCGCTATTATTGTTGGTATCCAAAC | | | | | | | | | |
| S Q S L L H S S G N T Y L N W L L Q R T G Q S P Q P L I Y L V S K > | | | | | | | | | |
| 610 620 630 640 650 660 670 680 690 700 | | | | | | | | | |
| TGGAATCTGGGTCCCCAACAGGTCTCAGTGGCAGTGGTCAGGAACAGATTCAACTCAAATCAGTGGAGCTGAGGATTGGGGTTTATTA | | | | | | | | | |
| L E S G V P N R F S G S G T D F T L K I S G V E A E D L G V Y Y > | | | | | | | | | |
| 710 | | | | | | | | | |
| * | * | * | * | * | * | * | * | * | * |
| CTGCATGCAATTACCAATTATCCGTCACACGTTGGAGCTGGGACCAAGCTGAACTGAA | | | | | | | | | |
| C M Q F T H Y P Y T F G A G T K L E L K > | | | | | | | | | |
| 100 | | | | | | | | | |

Fig-29

LoCD2a VII + Native Leader Sequence

Sequence Range: 1 to 491

Figure 30

5/17/95

Digitized by srujanika@gmail.com

Light Chain Variable Region Sequences of rat LO-CD2a,
human HUM5400, and humanized LO-CD2a

| | FR 1 | CDR 1 | FR 2 |
|------------------|------------|------------|-----------------------------|
| | * | 20 | 30 |
| Rat LO-CD2a Vk | DVVLTQTPPT | LLATIGQSVS | 40 ** |
| Humanized Vk | ---M--S--S | --V-L--PA- | -----P----- |
| Human HUM5400 Vk | ---M--S-LS | -PV-L--PA- | -----V Y-D---H--- PQ--P---R |

| | CDR 2 | FR 3 | CDR 3 |
|------------------|-------------|-------------|-------------------------|
| | 60 | 70 | 80 * 90 |
| Rat LO-CD2a Vk | PLIYLVSKLE | SGVPNRFSGS | 100 |
| Humanized Vk | -----D----- | GSCTDFTLKI | -----V----- |
| Human HUM5400 Vk | R---K---NRD | -----D----- | -----R-----V-----G---W- |

| | FR 4 |
|------------------|------------|
| | 110 |
| Rat LO-CD2a Vk | YTFGAGTKLE |
| Humanized Vk | ---Q----- |
| Human HUM5400 Vk | I----- |

31

09056072-040298

Humanized LO-CD2a Light Chain v Reggoli

Sequence Range: 1 to 807

TCGATCC

Fig. 32

5/17/95

Heavy Chain Variable Region Sequences of rat LO-CD2a,
human Amu 5-3, and humanized LO-CD2a

| | FR 1 | CDR 1 | FR 2 |
|------------------|--|---|------|
| | 10 20 30 40 * 50 | | |
| Rat LO-CD2a Vh | EVQLQQSGPE LQRPGASVKL SCKASGYIFT EYYMYWVYQR PKQGLELVGR | | |
| Humanized Vh | Q---V---A- VKK-----V -----T-- -----A- G-----M-- | | |
| Human Amu 5-3 Vh | Q---V---A- VKK-----V -----T-- G---H---R-A- G---W--- | | |
| | | CDR 2 | FR 3 |
| | | 60 * * * * 80 * * 90 100 | |
| Rat LO-CD2a Vh | IDPEDGSIDY VEKFKKKATL TADTSSNTAY MQLSSLTSED TATYFCARGK | | |
| Humanized Vh | ----- -----V-- -----S--- -E-----D- --V-Y----- | | |
| Human Amu 5-3 Vh | -N-NS-GTN- AQ--QGRV-M -R---IS--- -E--R-R-D- --V-Y---R | | |
| | | CDR 3 | FR 4 |
| | | 110 | |
| Rat LO-CD2a Vh | FNYR//FAYWGQ GTLVTVSS | | |
| Humanized Vh | ----//---- ----- | | |
| Human Amu 5-3 Vh | TE-IVVAEG-D----- | | |

Fig. 33

09056022-04022962

Humanized LO-CD2a Heavy chain V region

Sequence Range: 1 to 701

6

Fig. 34

5/17/95

Binding of LO-CD2a and LO-CD2a Hu to Jurkat Cells




Fig. 35

Induction of Hyporesponsiveness *in vitro*




Fig. 36





Fig. 37A

09056076-040793



117 378





Fig. 37C



210. 362

09056026 "0402798




Fig. 3B




Fig. 39

2020th 2095060




Fig. 40

000000000000000000000000




Fig 41